Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 153

1.

Screening for urinary tract colonisation prior to corticosteroid administration in acute multiple sclerosis relapses: Validation of an updated algorithm.

O'Herlihy F, John NA, Li V, Porter B, Lyons L, Rakusa M, Curtis C, Panicker JN, Chataway J.

J Neurol Sci. 2019 Sep 16;407:116456. doi: 10.1016/j.jns.2019.116456. [Epub ahead of print]

PMID:
31618683
2.

The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials.

Chataway J, Weir CJ, Fox RJ.

Mult Scler. 2019 Jun 20:1352458519856985. doi: 10.1177/1352458519856985. [Epub ahead of print] No abstract available.

PMID:
31218918
3.

Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.

John N, Carroll A, Brownlee WJ, Chataway J.

J Neurol Neurosurg Psychiatry. 2019 May 11. pii: jnnp-2019-320687. doi: 10.1136/jnnp-2019-320687. [Epub ahead of print] No abstract available.

PMID:
31079064
4.

Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis.

Eshaghi A, Kievit RA, Prados F, Sudre CH, Nicholas J, Cardoso MJ, Chan D, Nicholas R, Ourselin S, Greenwood J, Thompson AJ, Alexander DC, Barkhof F, Chataway J, Ciccarelli O.

Proc Natl Acad Sci U S A. 2019 May 28;116(22):11020-11027. doi: 10.1073/pnas.1818978116. Epub 2019 May 9.

5.

Novel Multiple Sclerosis Drugs in the Pipeline.

De Angelis F, Chataway J.

Clin Pharmacol Ther. 2019 May;105(5):1082-1090. doi: 10.1002/cpt.1412. No abstract available.

PMID:
30986336
6.

Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin.

Lanzillo R, Moccia M, Russo CV, Carotenuto A, Nozzolillo A, Petruzzo M, Palladino R, Chataway J, Brescia Morra V.

Mult Scler Relat Disord. 2019 Feb;28:193-196. doi: 10.1016/j.msard.2018.12.042. Epub 2019 Jan 2.

PMID:
30623857
7.

Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis.

Eskyte I, Manzano A, Pepper G, Pavitt S, Ford H, Bekker H, Chataway J, Schmierer K, Meads D, Webb E, Potrata B.

Mult Scler Relat Disord. 2019 Jan;27:370-377. doi: 10.1016/j.msard.2018.11.016. Epub 2018 Nov 17. Review.

PMID:
30476873
8.

Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era.

Lynch DS, Wade C, Paiva ARB, John N, Kinsella JA, Merwick Á, Ahmed RM, Warren JD, Mummery CJ, Schott JM, Fox NC, Houlden H, Adams ME, Davagnanam I, Murphy E, Chataway J.

J Neurol Neurosurg Psychiatry. 2019 May;90(5):543-554. doi: 10.1136/jnnp-2018-319481. Epub 2018 Nov 22. Review.

9.

Identifying barriers to help-seeking for sexual dysfunction in multiple sclerosis.

Tudor KI, Eames S, Haslam C, Chataway J, Liechti MD, Panicker JN.

J Neurol. 2018 Dec;265(12):2789-2802. doi: 10.1007/s00415-018-9064-8. Epub 2018 Sep 19.

PMID:
30232609
10.

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.

Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J; UK Multiple Sclerosis Society Clinical Trials Network.

BMJ Open. 2018 Aug 30;8(8):e021944. doi: 10.1136/bmjopen-2018-021944.

11.
12.

Innovation as a Driver of Quality and Productivity in UK Healthcare: Creating and Connecting Receptive Places-Emerging Insights.

Marjanovic S, Sim M, Dubow T, Corbett J, Harte E, Parks S, Miani C, Chataway J, Ling T.

Rand Health Q. 2018 Mar 30;7(4):1. eCollection 2018 Mar.

13.

Immune-mediated encephalitis with daclizumab: The final nail.

Williams T, Chataway J.

Mult Scler. 2019 Apr;25(5):753-754. doi: 10.1177/1352458518791374. Epub 2018 Aug 3.

PMID:
30073908
14.

Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.

De Angelis F, Plantone D, Chataway J.

CNS Drugs. 2018 Jun;32(6):499-526. doi: 10.1007/s40263-018-0538-0. Review.

PMID:
29968175
15.

2017 McDonald diagnostic criteria: A review of the evidence.

McNicholas N, Hutchinson M, McGuigan C, Chataway J.

Mult Scler Relat Disord. 2018 Aug;24:48-54. doi: 10.1016/j.msard.2018.05.011. Epub 2018 Jun 21. Review.

PMID:
29936325
16.

Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial.

Bonati LH, Gregson J, Dobson J, McCabe DJH, Nederkoorn PJ, van der Worp HB, de Borst GJ, Richards T, Cleveland T, Müller MD, Wolff T, Engelter ST, Lyrer PA, Brown MM; International Carotid Stenting Study investigators.

Lancet Neurol. 2018 Jul;17(7):587-596. doi: 10.1016/S1474-4422(18)30195-9. Epub 2018 Jun 1.

17.

Validating the portal population of the United Kingdom Multiple Sclerosis Register.

Middleton RM, Rodgers WJ, Chataway J, Schmierer K, Rog D, Galea I, Akbari A, Tuite-Dalton K, Lockhart-Jones H, Griffiths D, Noble DG, Jones KH, Al-Din A, Craner M, Evangelou N, Harman P, Harrower T, Hobart J, Husseyin H, Kasti M, Kipps C, McDonnell G, Owen C, Pearson O, Rashid W, Wilson H, Ford DV.

Mult Scler Relat Disord. 2018 Aug;24:3-10. doi: 10.1016/j.msard.2018.05.015. Epub 2018 May 25.

PMID:
29860199
18.

Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.

Marshall I, Thrippleton MJ, Bastin ME, Mollison D, Dickie DA, Chappell FM, Semple SIK, Cooper A, Pavitt S, Giovannoni G, Wheeler-Kingshott CAMG, Solanky BS, Weir CJ, Stallard N, Hawkins C, Sharrack B, Chataway J, Connick P, Chandran S; MS-SMART Trialists.

J Neurol. 2018 Aug;265(8):1795-1802. doi: 10.1007/s00415-018-8903-y. Epub 2018 May 30.

19.

Tackling progression in multiple sclerosis.

Chataway J.

Lancet Neurol. 2018 Jun;17(6):489-491. doi: 10.1016/S1474-4422(18)30158-3. No abstract available.

PMID:
29778353
20.

Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.

Chataway J, Martin K, Barrell K, Sharrack B, Stolt P, Wraith DC; ATX-MS1467 Study Group.

Neurology. 2018 Mar 13;90(11):e955-e962. doi: 10.1212/WNL.0000000000005118. Epub 2018 Feb 21.

PMID:
29467307

Supplemental Content

Loading ...
Support Center